ATE444363T1 - Il-21-antagonisten - Google Patents

Il-21-antagonisten

Info

Publication number
ATE444363T1
ATE444363T1 AT02773925T AT02773925T ATE444363T1 AT E444363 T1 ATE444363 T1 AT E444363T1 AT 02773925 T AT02773925 T AT 02773925T AT 02773925 T AT02773925 T AT 02773925T AT E444363 T1 ATE444363 T1 AT E444363T1
Authority
AT
Austria
Prior art keywords
antagonists
helix
mutations
polypeptides
specificity
Prior art date
Application number
AT02773925T
Other languages
English (en)
Inventor
Scott Presnell
James West
Julia Novak
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE444363T1 publication Critical patent/ATE444363T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02773925T 2001-11-05 2002-10-28 Il-21-antagonisten ATE444363T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33758601P 2001-11-05 2001-11-05
PCT/US2002/034502 WO2003040313A2 (en) 2001-11-05 2002-10-28 Il-21 antagonists

Publications (1)

Publication Number Publication Date
ATE444363T1 true ATE444363T1 (de) 2009-10-15

Family

ID=23321131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02773925T ATE444363T1 (de) 2001-11-05 2002-10-28 Il-21-antagonisten

Country Status (11)

Country Link
US (3) US6929932B2 (de)
EP (2) EP2130919A1 (de)
JP (2) JP2005508179A (de)
AT (1) ATE444363T1 (de)
AU (1) AU2002336676A1 (de)
CA (1) CA2465156C (de)
DE (1) DE60233888D1 (de)
DK (1) DK1451322T3 (de)
ES (1) ES2334338T3 (de)
MX (1) MXPA04004167A (de)
WO (1) WO2003040313A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
JP2002516103A (ja) * 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン２１およびインターロイキン２２
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
ES2604352T3 (es) 2003-02-05 2017-03-06 Iquum, Inc. Procesado de muestras
ATE456581T1 (de) 2003-03-14 2010-02-15 Wyeth Corp Antikörper gegen il21-rezeptor und deren verwendung
EP1608315A4 (de) * 2003-03-21 2008-07-16 Wyeth Corp Behandlung von immunologischen störungen mit agonisten von interleukin-21/ interleukin-21 rezeptor
CA2529520A1 (en) * 2003-06-19 2004-12-29 Centocor, Inc. Interleukin-21 analogs
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
JP2007533298A (ja) * 2003-10-10 2007-11-22 ノボ　ノルディスク　アクティーゼルスカブ Ｉｌ−２１の誘導体
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
DK1692276T3 (da) 2003-11-19 2010-11-01 Us Gov Health & Human Serv Fremgangsmåde til induktion af udvikling og terminal differentiering af hukommelses-B-celler
CA2551879A1 (en) * 2004-01-15 2005-07-28 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
EP1612892B1 (de) * 2004-06-30 2008-03-19 Tyco Electronics Nederland B.V. Verbinder für elektronische Bauteile
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
ATE497975T1 (de) 2005-04-18 2011-02-15 Novo Nordisk As Il-21-varianten
AU2006256802A1 (en) * 2005-06-06 2006-12-14 Novo Nordisk A/S Stabilised IL-21 compositions
EP2805971A1 (de) 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21-Antagonisten
US20080003564A1 (en) * 2006-02-14 2008-01-03 Iquum, Inc. Sample processing
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
AU2007336184A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
EP2217268B1 (de) 2007-12-07 2016-05-04 ZymoGenetics, Inc. Monoklonale antii-human-il-21-antikörper
EP2238241B1 (de) 2008-01-18 2013-09-11 The Brigham and Women's Hospital, Inc. Selektive differenzierung, identifizierung und modulation menschlicher th17-zellen
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
CA2725154A1 (en) * 2008-05-23 2009-11-26 Wyeth Llc Methods of treatment utilizing binding proteins of the interleukin-21 receptor
LT2344677T (lt) 2008-10-08 2017-09-25 Cambridge Enterprise Limited Metodai ir kompozicijos, skirti antrinės išsėtinei sklerozei autoimuninės ligos diagnozavimui ir gydymui
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
EP2596023A4 (de) * 2010-07-20 2014-03-05 Beth Israel Hospital Zusammensetzungen und verfahren mit il-6- und il-21-antagonisten
RS60050B1 (sr) 2011-01-18 2020-04-30 Bioniz Llc Kompozicije za modulaciju aktivnosti gama-c-citokina
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
HK1247622A1 (zh) 2015-03-02 2018-09-28 180 Therapeutics Lp 利用il-33拮抗剂来治疗局部纤维化的方法
HUE056544T2 (hu) 2015-10-09 2022-02-28 Bioniz Llc Gamma-C-citokin aktivitás modulálása
CA3059634A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
ES2910969T3 (es) 2017-08-03 2022-05-17 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
WO2019140196A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4340866A4 (de) 2021-05-19 2025-05-21 Asher Biotherapeutics, Inc. Il-21-polypeptide und gezielte konstrukte

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4990446A (en) 1984-12-06 1991-02-05 Labofina, S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
DE721983T1 (de) 1988-01-22 2002-07-04 Zymogenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
CA2144651A1 (en) 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1997017451A2 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
CA2261151C (en) 1996-07-17 2003-09-16 Zymogenetics, Inc. Transformation of pichia methanolica
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
HU229148B1 (en) 1999-03-09 2013-09-30 Zymogenetics Inc Seattle Human cytokine as ligand of the zalpha receptor and uses thereof
AU2003230834A1 (en) 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US9418201B1 (en) 2015-11-19 2016-08-16 International Business Machines Corporation Integration of functional analysis and common path pessimism removal in static timing analysis

Also Published As

Publication number Publication date
US7186805B2 (en) 2007-03-06
EP2130919A1 (de) 2009-12-09
ES2334338T3 (es) 2010-03-09
JP2005508179A (ja) 2005-03-31
AU2002336676A1 (en) 2003-05-19
DK1451322T3 (da) 2010-02-01
EP1451322A2 (de) 2004-09-01
DE60233888D1 (de) 2009-11-12
WO2003040313A3 (en) 2003-09-25
US6929932B2 (en) 2005-08-16
MXPA04004167A (es) 2004-07-08
EP1451322B1 (de) 2009-09-30
CA2465156C (en) 2011-10-18
JP2010207238A (ja) 2010-09-24
US20070166796A1 (en) 2007-07-19
US20050244930A1 (en) 2005-11-03
US20030134390A1 (en) 2003-07-17
EP1451322A4 (de) 2005-02-02
CA2465156A1 (en) 2003-05-15
WO2003040313A2 (en) 2003-05-15
US7410780B2 (en) 2008-08-12

Similar Documents

Publication Publication Date Title
ATE444363T1 (de) Il-21-antagonisten
DE10192353T1 (de) Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung
EP1713825A4 (de) Polypeptide mit cellulolytisch verstärkender wirkung und dafür codierende polynukleotide
JP2008503230A5 (de)
ATE270674T1 (de) Neue n-phenylpyrrolbisphosphanverbindungen und deren metallkomplexe
CY1118951T1 (el) Χρηση αντισωματων υποδοχεα ιντερλευκινης-4 και συνθεσεις αυτων
DK2277997T3 (da) Polypeptider med cellobiohydrolase I-aktivitet og polynukleotider, der koder for samme
NL1021695A1 (nl) Thermisch stabiele mengsels van een in hoge mate paraffinische destillaatbrandstofcomponent en een gebruikelijke destillaatbrandstofcomponent.
EP2949658A3 (de) Spezifisch an HGF-Rezeptor (cMet) bindende Peptide und deren Verwendung
EP1436309A4 (de) Bgl3-beta-glukosidase und für diese codierende nucleinsäuren
DE60132709D1 (de) Bestimmung der wirksamen zusammensetzung von kohlenwasserstoffgasen
EP1453968A4 (de) Bgl4-beta-glucosidase und diese codierende nukleinsäuren
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DE60237851D1 (de) Modifiziertes Propylenpolymer, dieses enthaltende Zusammensetzung und deren Verwendung
HUT77572A (hu) CD23-hoz kötődő vegyületek
WO2005019270A3 (en) Endotheliase-2 ligands
SI1373503T1 (sl) Nevtroficni dejavniki
DE50002001D1 (de) Anordnung zum verhältnisgleichen Ausbringen von zwei fliessfähigen Substanzen, insbesondere für Dentalzwecke
PT1265612E (pt) Composicao farmaceutica compreendendo pemetrexed conjuntamente com monotioglicerol l- cisteina ou acido tioglicolico
DE60039999D1 (de) Bindungsoberfläche
JP2004500380A5 (de)
WO2005105842A3 (en) Crystal structure of cytochrome p450 3a4 and uses thereof
DE60139770D1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
JP2004511237A5 (de)
DE59811656D1 (en) Kombinationspräparat aus 2-methylthiazolidin-2,4-dicarbonsäure und paracetamol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1451322

Country of ref document: EP